Tag Archives: Taxes/regulation

The last long leading indicator, corporate profits, declined in Q4 2018 Three months after the quarter ended, corporate profits for Q4 of 2018 were reported this morning, and they were down slightly (-0.1%). Here’s the quote from the BEA: Corporate profits deflated by unit labor costs are a long leading indicator. Since these costs were already reported at +1.6% q/q, that means that adjusted corporate profits were down about the same percentage....

by New Deal democrat February housing data indicates slump not over UPDATED Housing data, in the form of February permits and starts, finally caught up after the government shutdown. Two sources of house price data were also released this morning. The bottom line is that, depending on how you measure, housing construction is likely either at or just slightly above a short term bottom. Price growth, meanwhile, continues to decelerate. I have a more...

by New Deal democrat Weekly Indicators for March 18 – 22 at Seeking Alpha My Weekly Indicators post is up at Seeking Alpha. As you can imagine, the big news was about the fact that almost every single yield curve there is – except the one I report on every week in that post – inverted yesterday. Also, as I mentioned in an e-mail to a couple of folks this morning, the big thing that bothers me is that ***EVERYONE*** is watching it. And a forecasting tool...

No More Fed Rate Hikes in 2019… The fundamentals are “sound”?: PICTURE = 1000 WORDS

by New Deal democrat The widened Panama Canal is disrupting internal US transportation patterns The newly-widened Panama Canal opened to traffic in late 2016. Since then, there have been several ongoing disruptions in how goods are transported from suppliers in Asia to their ultimate markets in the US, including affects on seaports, trucking, and rail. This post is up at Seeking Alpha.  As usual, clicking over and reading should be educational for you,...

The government shutdown may have caused a mini-recession Aside from being a monumentally poor policy outcome, and aside from the hardship it caused nearly a million workers, the government shutdown may also have caused a general contraction in production, sales, and income, and a slowdown in employment, that if it were longer would qualify as a recession. Because the affected three months straddle Q4 2018 and Q1 2019, both quarters will likely show...

I just had an unusual experience. I was convinced by an op-ed. One third of the way through “Elizabeth Warren Actually Wants to Fix Capitalism” by David Leonhardt, I was planning to contest one of Leonhard’s assertions. Now I am convinced. The column praises Elisabeth Warren. Leonhardt (like his colleague Paul Krugman) is careful to refrain from declaring his intention to vote for her in the primary. I am planning to vote for her. I mostly agreed with...

Negative Nov. and Dec. revisions overwhelm positive January retail sales The initial spin on this morning’s delayed retail sales report for January has been positive, with for example the Wall Street Journal calling it a “rebound” and “a sign of solid economic momentum in the first quarter. Ummmmm, No. Both nominally and in real terms, retails sales did improve by +0.2% in January over December. The problem is, both November and December were revised...

A modest proposal to use FICA-style tax withholding as a transition to “Medicare for All” Probably the foremost reform advanced by the Democratic Party at present is “Medicare for All.” Personally I don’t particularly care whether it is ultimately necessary to have single payer (like Canada) or universal coverage (like France or Germany) or a hybrid of each (like Australia). I am fond of the Japanese saying that translates as “There are many paths to the...

The Trump Tax Cut and Big Pharma CEOs of 7 pharmaceutical multinationals addressed the Senate Finance Committee: Pharma execs offer Senate ideas to lower drug costs – except actually cutting prices. Executives from seven pharmaceutical companies — AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi — are testifying before the Senate Finance Committee. The pharma executives have a number of ideas to reduce drug...